No Data
No Data
No Data
Imeik technology development (300896.SZ): The registration and listing license for type A botulinum toxin for injection has been accepted.
On July 3rd, Gelunhui reported that Imeik Technology Development (300896.SZ) recently received the "Acceptance Notice" (Acceptance Number: JXSS2400051) issued by the National Medical Products Administration, and learned that the company's overseas production drug registration and listing application has been accepted. The product name is type A botulinum toxin for injection. With the continuous development of the industry, the company has formed complementary advantages between different products through differentiated positioning and increased research and development efforts, meeting the needs of customers at different levels. After the launch of type A botulinum toxin for injection, it will work in tandem with the company's existing medical instruments products to provide more comprehensive medical beauty services.
As of June 28th, 2024, imeik technology development (300896.SZ) had 58,782 shareholders.
On July 1st, Gelonhui reported that as of June 28, 2024, imeik technology development (300896.SZ) had 58,782 shareholders on its investor relations platform.
Imeik technology development (300896.SZ): The Simigeptide injection project is currently in the pre-clinical research stage.
On June 21, Gelonhui reported that imeik technology development (300896.SZ) stated on the investor interaction platform that the company's Siglutech peptide injection project is currently in the preclinical research stage.
Recent 7.1% Pullback Would Hurt Imeik Technology Development Co.,Ltd. (SZSE:300896) Insiders
Key Insights Insiders appear to have a vested interest in Imeik Technology DevelopmentLtd's growth, as seen by their sizeable ownership 52% of the business is held by the top 5 shareholders Insti
Are Investors Undervaluing Imeik Technology Development Co.,Ltd. (SZSE:300896) By 27%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Imeik Technology DevelopmentLtd fair value estimate is CN¥306 Imeik Technology DevelopmentLtd is estimated to be 27% undervalued based on cur
The quarterly report verifies the strong growth in performance, why is Aimeike (300896.SZ) making strong players stronger?
In recent years, with the improvement of living standards, people have begun to pursue a higher level of spiritual life, and the face value economy has made great strides. According to a report published by Tencent Marketing Insights, the Chinese medical beauty market has grown at a compound annual growth rate of 17.5% since 2017 to nearly 190 billion dollars in 2021. However, due to multiple factors such as changes in residents' income expectations, the growth rate of medical and aesthetic consumption began to slow in 2022. The Zhitong Finance App notes that under the pessimistic expectations of the market, medicine and beauty have been questioned a lot over the past year or so as an “improved” optional consumption.
No Data